June 08, 2026 —
A new study published in Neuron suggests that an experimental gene therapy strategy may help prevent and reverse levodopa-induced dyskinesia, a common complication of long-term Parkinson’s disease treatment.
Levodopa remains one of the most effective therapies for Parkinson’s disease, helping replace dopamine as dopamine-producing neurons are progressively lost. However, many patients who take levodopa over time develop dyskinesia, or uncontrolled involuntary movements. According to the study summary, nearly 80% of Parkinson’s disease patients may eventually develop dyskinesia, and current treatment options remain limited.
Researchers found that dyskinesia was linked to abnormal levels of GluN2B, a subunit of NMDA receptors, in a specific group of movement-control neurons called indirect pathway spiny projection neurons, or iSPNs. These neurons normally help suppress unwanted movement, but repeated levodopa treatment appeared to disrupt synaptic signaling in this pathway.
Using a mouse model, the researchers tested an experimental gene therapy strategy designed to reduce GluN2B levels specifically in iSPNs. The treatment not only blunted the development of dyskinesia when given before repeated levodopa exposure, but also substantially eased established dyskinesia after it had already developed.
Importantly, reducing GluN2B did not reduce levodopa’s ability to relieve Parkinson’s motor symptoms. This suggests that the approach may be able to address dyskinesia without compromising the core symptomatic benefit of levodopa treatment.
The findings point to a new therapeutic concept for Parkinson’s disease: correcting the synaptic circuit changes that drive dyskinesia rather than simply adjusting dopamine replacement therapy. While the work remains preclinical and further studies are needed to evaluate safety, durability, and translational feasibility, the results suggest a potential non-invasive gene therapy strategy for a major unmet need in Parkinson’s care.
If successfully translated, targeting GluN2B in specific striatal neurons could offer a new way to manage levodopa-induced dyskinesia and improve quality of life for patients with advanced Parkinson’s disease.
